A. Farris

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial

Giorgio Mustacchi, Rita Ceccherini, Stefano Milani et al. · Annals of Oncology · 2003 · 203 citations · Full text

Medicine, Geriatric Medicine, Oncology +10

Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial

Francesco Boccardo, A. Rubagotti, D. Amoroso et al. · Journal of Clinical Oncology · 2000 · 185 citations

Pharmacy, Oncology, Pharmacotherapy +17

Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa

Paolo Pedrazzoli, A. Farris, Salvatore Del Prete et al. · Journal of Clinical Oncology · 2008 · 168 citations · Full text

Medicine, Hematology, Pharmacology +17

Capecitabine plus oxaliplatin for the first‐line treatment of elderly patients with metastatic colorectal carcinoma

Pasquale Comella, D. Natale, A. Farris et al. · Cancer · 2005 · 91 citations · Full text

Medicine, Oncology, Pharmacology +15

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 88 citations · Full text

Medicine, Endocrinology, Oncology +11